Kinetisol® Technology: Broader. Faster. Greener.

The pharmaceutical industry is constantly striving to develop drugs that are more effective and efficient. One major challenge the industry faces is the poor solubility of many drug compounds. To overcome this issue, the industry has turned to amorphous solid dispersions (ASDs), which can enhance drug solubility and bioavailability. However, the traditional methods of producing ASDs often involve the use of organic solvents, which not only have negative environmental impacts but also add complexity and cost to the manufacturing process.

Enter AustinPx's KinetiSol Technology, an innovative solvent-free alternative for the production of ASDs. This technology not only addresses the solubility issue but also offers a range of benefits that make it a superior choice for pharmaceutical manufacturers. By eliminating the need for organic solvents, KinetiSol Technology significantly reduces the carbon footprint of ASD manufacturing, making it a greener and more sustainable solution.

KinetiSol Technology also offers faster processing times, allowing for more efficient production. It provides a broader formulation design space, giving manufacturers greater flexibility and control in developing ASDs. Additionally, the technology improves overall manufacturability, resulting in higher-quality products.

Already, KinetiSol Technology has been successfully applied to over sixty molecules, revolutionizing the ASD manufacturing process. With its solvent-free approach and impressive results, it is a step towards a more sustainable future for the pharmaceutical industry. By embracing this cutting-edge technology, pharmaceutical manufacturers can not only enhance drug solubility and bioavailability but also contribute to reducing carbon dioxide emissions and protecting the environment.